SCHEMBL22402643

SCHEMBL22402643

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)C(F)C1O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 4/20 0.83
▸ P2RY2 P41231 3/20 0.83
▸ SRC P12931 2/20 0.83
▸ SMN1; SMN2 Q16637 2/20 0.83
▸ DNPH1 O43598 1/20 0.83
▸ PRKAB2 O43741 1/20 0.83
▸ TRPM2 O94759 1/20 0.83
▸ LDHA P00338 1/20 0.83
▸ ADRB2 P07550 1/20 0.83
▸ FBP1 P09467 1/20 0.83
▸ ADORA1 P30542 1/20 0.83
▸ PRKAG1 P54619 1/20 0.83
▸ PRKAA2 P54646 1/20 0.83
▸ PDE4D Q08499 1/20 0.83
▸ KCNH2 Q12809 1/20 0.83
▸ PRKAA1 Q13131 1/20 0.83
▸ PDE3A Q14432 1/20 0.83
▸ TAS1R3 Q7RTX0 1/20 0.83
▸ TAS1R1 Q7RTX1 1/20 0.83
▸ P2RY11 Q96G91 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8862549 1.00 P2RY1 (0.83) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL26361720 1.00 P2RY1 (0.83) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL22393014 1.00 P2RY1 (0.83) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL8862545 1.00 P2RY1 (0.83) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL24254557 0.92 P2RY1 (0.71) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL26255276 0.92 P2RY1 (0.71) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL26255761 0.92 P2RY1 (0.71) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL31448299 0.92 P2RY1 (0.83) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL8862541 0.92 P2RY1 (0.83) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL8836314 0.92 P2RY1 (0.83) P2RY1P2RY2SRCSMN1; SMN2DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 — — US disclosed
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 — — US disclosed
US-20220017560-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) 2022-01-20 — — US disclosed
US-11186606-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-11-30 — — US disclosed
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-10-19 — — US disclosed
US-20200283468-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 LUMINEX INTERNATIONAL (CN) 2020-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017560-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SRC 924/4885
US-11186606-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SRC 924/4885
US-20200283468-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SRC 924/4885
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SRC 924/4885
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SRC 924/4885
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SRC 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback